PH-responsive tumor-targeted drug delivery

Last updated

pH-responsive tumor-targeted drug delivery is a specialized form of targeted drug delivery that utilizes nanoparticles to deliver therapeutic drugs directly to cancerous tumor tissue while minimizing its interaction with healthy tissue. [1] Scientists have used drug delivery as a way to modify the pharmacokinetics and targeted action of a drug by combining it with various excipients, drug carriers, and medical devices. [2] These drug delivery systems have been created to react to the pH environment of diseased or cancerous tissues, triggering structural and chemical changes within the drug delivery system. [3] This form of targeted drug delivery is to localize drug delivery, prolongs the drug's effect, and protect the drug from being broken down or eliminated by the body before it reaches the tumor.

Contents

Tumor Environment

The microenvironment of a tumor is different compared to normal healthy tissues in the body. One distinct difference is the pH levels. The human body overall tends to have a more alkaline pH level of 7.4 while tumor tissue ranges from 7.0- 7.2 pH level, which is known as tumor acidosis. [4] Tumor acidosis can occur due to various factors, including hypoxia, the Warburg effect, and the release of acidic metabolites by the tumor cells. [5]

Tumor hypoxia occurs when a tumor’s environment has low or severely depleted oxygen levels compared to healthy tissue, which could lead to tumor acidosis. [6] Rapidly reproducing tumor cells become more extensive in size and do not have a sufficient blood supply.  Some studies show that this leads tumor environments to become hypoxic, which then leads to metabolic changes. [7]

The Warburg Effect refers to cancer cells using aerobic glycolysis for cell metabolism, which results in an increased rate of glucose uptake and a preference for lactate production, despite the presence of oxygen. [8] It is still unknown why cancer cells switch their metabolism method as it is energy inefficient. Even though this method is inefficient in producing ATP, some studies show that cancer cells may be using aerobic glycolysis to produce energy because it is faster than the normal process of respiration. [8] This process allows these malignant cells to produce energy quickly. This is particularly useful in an environment where they must rapidly grow and divide. [7] The acidic metabolite build-up occurs due to an excess of lactate production. [9]

As a result, targeting the acidic microenvironment of tumors has emerged as a promising strategy for cancer therapy. One approach involves the use of creating drug delivery carriers that are sensitive to pH levels and have triggered drug release at the tumor site, thereby enhancing the efficacy of chemotherapy and other treatments. [10]

Mechanism of pH-responsive tumor-targeted drug delivery

Mechanisms

pH-responsive tumor-targeted drug delivery detects the changes in the pH within the body. These polymer drug carriers carry the therapeutic drugs to allow for targeted drug delivery. The purpose of the pH- triggered drug release is to deliver the drug precisely to the area of the tumor and not activate and release the drug in healthy tissue. [1] The complex compromises a drug delivery unit made up of a carrier molecule made up of organic nanomaterials, inorganic nanomaterials, composite nanomaterials, and anti-tumor drugs. The carrier compromises pH-sensitive molecules, which allows the drug vehicle to activate at the tumor site at the optimal pH range it is set to get triggered at and release the drug. [11]

The loading of anti-tumor drugs into pH-responsive polymer nanomaterials can be classified into three categories: chemical bonding, intermolecular force, and physical encapsulation. [12] These loading mechanisms allow the drug to stay within the carrier until the tumor environment has been reached. In addition, the carrier can be engineered to have the ability to modify its structure or properties in response to the pH change. Common pH-sensitive structures include chemical bonds that hydrolyze or break in acidic environments, polymers that change their charge properties with pH changes, and other special pH-responsive polymers. [13] [11] For example, two possible mechanisms could be applied: incorporating protonatable groups or forming acid-labile bonds. When exposed to the low pH, pH-triggered protonation/ionization changes create disturbances of the hydrophilic-hydrophobic balance within the nanocarrier, causing its disassembly and releasing the drug encapsulated within the carrier. [13] Common ionizable groups used include amino, carboxyl, sulfonate, and imidazolyl. Depending on the introduced functional group's acid dissociation constant (pKa), drug release from these nanocarriers can occur through precipitation, aggregation, or dissociation mechanisms. [10] Another possible carrier could be lipid-based, and a drop in pH can cleave the covalent acid-labile bonds on the surface and within the carrier leading to swelling of the drug delivery system and then release of the drug at a specific rate. [10]

Advantages of pH-responsive tumor-targeted drug delivery

Studies have shown pH-responsive tumor-targeted drug delivery carriers to have advantages. One key advantage is the increased specificity targeting the tumor cells and comparatively low cytotoxicity compared to other therapy methods. [14] The low toxicity results from reducing the drug or therapy exposure to healthy tissue due to the targeted approach of this drug delivery method. [15] Another aspect noticed during previous studies is the efficiency in drug release rate. The drug carrier releases the anti-cancer drug when triggered by the tumor's low pH levels and these pH levels control the rate of drug release. [16] Drugs administered usually require frequent dosing, but with a drug delivery carrier, it allows for a gradual and sustained release of the drug leading cancer patients to not have to be in the clinic as much for treatment. [17]

Types of pH- responsive drug delivery vehicles

Hydrogel based pH- triggered Drug Delivery

Hydrogel Crosslinking Peptide hydrogel formation simplified scheme.png
Hydrogel Crosslinking

Hydrogels

Hydrogels are networks of polymers crosslinked to form a three-dimensional structure capable of absorbing and retaining large amounts of fluids. The polymer chains contain numerous hydrophilic groups such as -NH2, -OH, -COOH, and -SO3. With increased capillary action, hydrogels are relatively insoluble unless triggered by the change in pH for tumor-targeted drug carriers. [18] The physical properties of hydrogels can be adjusted to meet specific requirements for various drug delivery systems. pH-responsive hydrogels have been extensively developed recently and have proven particularly useful for targeted cancer treatment. They can prolong drug release and are quick and cost-effective to synthesize. [12]

PEG-PLGA hydrogel nanoparticles

In the past decade, scientists have been working on engineering an injectable hydrogel post- resection surgery to treat tumor sites. [19] Polylactide-co-glycolide (PLGA) and polyethylene glycol (PEG) hydrogel is an injectable biomaterial made up of is a copolymer, that has been approved by the Food and Drug Administration (FDA) for use in therapeutic devices due to its biodegradability and biocompatibility properties in the human body. [20] [19] There have been studies done in loading these hydrogels with cancer therapeutic drugs for localized treatment in breast tumors after surgical resection. Additionally, drug-loaded particles within the hydrogel have been proposed as dual-stimuli responsive drug delivery systems combining pH-responsivity with the temperature response of the PEGylated polyester gels. Studies show that these types of hydrogels can be used to treat tumors in lungs and bladders. [19]

Liposome/Micelle based pH- triggered Drug Delivery

Liposomes are made of phospholipids and contain small amounts of other molecules. This is one example of a type of drug delivery carrier that can be used for pH-responsive tumor targeted drug delivery. Liposome.jpg
Liposomes are made of phospholipids and contain small amounts of other molecules. This is one example of a type of drug delivery carrier that can be used for pH-responsive tumor targeted drug delivery.

Liposomes

Liposomes were first reported as drug-delivery vehicles in the 1960s and are biomimetic nanosomes composed of phospholipid bilayers. Due to their biocompatibility, biodegradability, and ability to encapsulate both hydrophilic and hydrophobic drugs, liposomes are a popular choice for pH-responsive tumor-targeted drug delivery. [12] [22] The liposome can be modified to facilitate triggered release in response to acidic environmental conditions. These can be prepared by adding pH-sensitive components to fabricate liposomes. pH-responsive liposomes generally consist of weakly acidic amphiphile such as cholesteryl hemisuccinate (CHEMS) and cone-shaped lipids such as Dioleoylphosphatidylethanolamine (DOPE). [23] DOPE adopts a bilayer structure at neutral pH but forms a hexagonal inverted structure, due to the low hydration of their polar head and neutralization of the negatively charged phosphodiester groups when exposed to acidic conditions, such as tumour sites, leading to destabilization and content release, while remaining stable at physiological pH. [23] [24] pH-responsive liposomes have some significant advantages, such as low toxicity, simple preparation, and good biocompatibility due to the biocompatible degradable components. [12]

Micelles

Micelle Diagram Micelle scheme-id.svg
Micelle Diagram

Micelles are typically formed through block polymers self-assembling which can be conjugated with different units, such as polyethylene glycol and poly(amino acid). Drug release from micelles is typically slow, resulting in low concentrations of free drugs in tumor cells and decreased therapeutic outcomes. However, introducing pH-sensitive chemical bonding arms between polymer chain segments or polymers will allow the micelle to hydrolyze quickly under weakly acidic conditions and work as an efficient drug delivery carrier for pH-responsive tumor-targeted drug delivery. [12]

PEGylated doxorubicin nanoparticles

PEGylated liposomal doxorubicin has been studied and show results of high drug loading capacity and pH-responsive drug release within the tumor cell or tissue region. [25] Doxorubicin is a widely used anti-cancer drug, but it has sever toxic side effects towards the cancer patients. To mitigate this, scientists are conducting tests to see how fabricating doxorubicin within the liposomal formulation can have an effect on potentially decreasing side effects through covalent bond interactions in the formation of this drug carrier type. [26]

Challenges and future direction

pH-triggered drug delivery systems are able to control the pharmacokinetics and the biodistribution of the drugs enclosed within the drug carrier and have a controlled release. Many “smart” pH-responsive drug delivery systems have not made it to clinical trials. [27] However, there still are many challenges with this treatment method. [10] Drug carriers for the pH-triggered release of tumors can be made out of many different combinations of materials depending on the tumor type. One of the popular materials to use is acrylamide or acrylic acid types of polymers. These polymers are harder to degrade in the body as they are not hydrolytically degradable. [27] Another concern is how effective these carriers are in reaching the target areas. There are different methods to create these carriers to maximize the drug delivery at the site, and each method poses its own potential risks to achieve making the drug carrier. [10] Some materials that could be used have higher molecular weights, which will not be able to be excreted via the kidneys after releasing the drug at the target area. [27] This leads to accumulation in the body and can lead to other problems.

Another major current issue is this drug delivery system's low accuracy and off-target delivery. The heterogeneity of the tumor pH is one of the reasons for this cause. The pH of the tumor tends to become more acidic as you reach the center of the tumor. [10] Another reason for off-target delivery could be due to the lower pH levels of lesions and inflammation sites. Studies show that this problem could be overcome by avoiding receptor-mediated active targeting with monoclonal antibodies. [10]

Besides the drugs, conducting clinical trials can also be very expensive. [28] When drug delivery systems tend to have high molecular weight and have a possibility of being toxic to the body due to build-up, companies tend to shy away from taking part in actively testing out these drugs clinically as it can pose a risk for the company in terms of monetary funds as well as ethical issues. [27]

With more research and in vitro and in vivo testing, a possible solution could be found to combat these challenges. This drug delivery treatment method can be used in combination with other cancer treatment methods such as chemotherapy, gene therapy, and a combination of these therapies. [29] [30]

Related Research Articles

<span class="mw-page-title-main">Anthracycline</span> Class of antibiotics

Anthracyclines are a class of drugs used in cancer chemotherapy that are extracted from Streptomyces bacterium. These compounds are used to treat many cancers, including leukemias, lymphomas, breast, stomach, uterine, ovarian, bladder cancer, and lung cancers. The first anthracycline discovered was daunorubicin, which is produced naturally by Streptomyces peucetius, a species of Actinomycetota. Clinically the most important anthracyclines are doxorubicin, daunorubicin, epirubicin and idarubicin.

A drug carrier or drug vehicle is a substrate used in the process of drug delivery which serves to improve the selectivity, effectiveness, and/or safety of drug administration. Drug carriers are primarily used to control the release of drugs into systemic circulation. This can be accomplished either by slow release of a particular drug over a long period of time or by triggered release at the drug's target by some stimulus, such as changes in pH, application of heat, and activation by light. Drug carriers are also used to improve the pharmacokinetic properties, specifically the bioavailability, of many drugs with poor water solubility and/or membrane permeability.

Targeted drug delivery, sometimes called smart drug delivery, is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more uniform effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult, and the reduced ability to adjust the dosages.

A nanogel is a polymer-based, crosslinked hydrogel particle on the sub-micron scale. These complex networks of polymers present a unique opportunity in the field of drug delivery at the intersection of nanoparticles and hydrogel synthesis. Nanogels can be natural, synthetic, or a combination of the two and have a high degree of tunability in terms of their size, shape, surface functionalization, and degradation mechanisms. Given these inherent characteristics in addition to their biocompatibility and capacity to encapsulate small drugs and molecules, nanogels are a promising strategy to treat disease and dysfunction by serving as delivery vehicles capable of navigating across challenging physiological barriers within the body. 

<span class="mw-page-title-main">Arginylglycylaspartic acid</span> Chemical compound

Arginylglycylaspartic acid (RGD) is the most common peptide motif responsible for cell adhesion to the extracellular matrix (ECM), found in species ranging from Drosophila to humans. Cell adhesion proteins called integrins recognize and bind to this sequence, which is found within many matrix proteins, including fibronectin, fibrinogen, vitronectin, osteopontin, and several other adhesive extracellular matrix proteins. The discovery of RGD and elucidation of how RGD binds to integrins has led to the development of a number of drugs and diagnostics, while the peptide itself is used ubiquitously in bioengineering. Depending on the application and the integrin targeted, RGD can be chemically modified or replaced by a similar peptide which promotes cell adhesion.

Microbubbles are bubbles smaller than one hundredth of a millimetre in diameter, but larger than one micrometre. They have widespread application in industry, medicine, life science, and food technology. The composition of the bubble shell and filling material determine important design features such as buoyancy, crush strength, thermal conductivity, and acoustic properties.

<span class="mw-page-title-main">Sonodynamic therapy</span>

Sonodynamic therapy (SDT) is a noninvasive treatment, often used for tumor irradiation, that utilizes a sonosensitizer and the deep penetration of ultrasound to treat lesions of varying depths by reducing target cell number and preventing future tumor growth. Many existing cancer treatment strategies cause systemic toxicity or cannot penetrate tissue deep enough to reach the entire tumor; however, emerging ultrasound stimulated therapies could offer an alternative to these treatments with their increased efficiency, greater penetration depth, and reduced side effects. Sonodynamic therapy could be used to treat cancers and other diseases, such as atherosclerosis, and diminish the risk associated with other treatment strategies since it induces cytotoxic effects only when externally stimulated by ultrasound and only at the cancerous region, as opposed to the systemic administration of chemotherapy drugs.

Polymer-drug conjugates are nano-medicine products under development for cancer diagnosis and treatment. There are more than 10 anticancer conjugates in clinical development. Polymer-drug conjugates are drug molecules held in polymer molecules, which act as the delivery system for the drug. Polymer drugs have passed multidrug resistance (MDR) testing and hence may become a viable treatment for endocrine-related cancers. A cocktail of pendant drugs could be delivered by water-soluble polymer platforms. The physical and chemical properties of the polymers used in polymer-drug conjugates are specially synthesized to flow through the kidneys and liver without being filtered out, allowing the drugs to be used more effectively. Traditional polymers used in polymer-drug conjugates can be degraded through enzymatic activity and acidity. Polymers are now being synthesized to be sensitive to specific enzymes that are apparent in diseased tissue. The drugs remain attached to the polymer and are not activated until the enzymes associated with the diseased tissue are present. This process significantly minimizes damage to healthy tissue.

<span class="mw-page-title-main">Nanocarrier</span>

A nanocarrier is nanomaterial being used as a transport module for another substance, such as a drug. Commonly used nanocarriers include micelles, polymers, carbon-based materials, liposomes and other substances. Nanocarriers are currently being studied for their use in drug delivery and their unique characteristics demonstrate potential use in chemotherapy. This class of materials was first reported by a team of researchers of University of Évora, Alentejo in early 1960's, and grew exponentially in relevance since then.

<span class="mw-page-title-main">Aldoxorubicin</span> Medication

Aldoxorubicin (INNO-206) is a tumor-targeted doxorubicin conjugate in development by CytRx. Specifically, it is the (6-maleimidocaproyl) hydrazone of doxorubicin. Essentially, this chemical name describes doxorubicin attached to an acid-sensitive linker.

Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.

<span class="mw-page-title-main">Dextran drug delivery systems</span> Polymeric drug carrier

Dextran drug delivery systems involve the use of the natural glucose polymer dextran in applications as a prodrug, nanoparticle, microsphere, micelle, and hydrogel drug carrier in the field of targeted and controlled drug delivery. According to several in vitro and animal research studies, dextran carriers reduce off-site toxicity and improve local drug concentration at the target tissue site. This technology has significant implications as a potential strategy for delivering therapeutics to treat cancer, cardiovascular diseases, pulmonary diseases, bone diseases, liver diseases, colonic diseases, infections, and HIV.

Conventional drug delivery is limited by the inability to control dosing, target specific sites, and achieve targeted permeability. Traditional methods of delivering therapeutics to the body experience challenges in achieving and maintaining maximum therapeutic effect while avoiding the effects of drug toxicity. Many drugs that are delivered orally or parenterally do not include mechanisms for sustained release, and as a result they require higher and more frequent dosing to achieve any therapeutic effect for the patient. As a result, the field of drug delivery systems developed into a large focus area for pharmaceutical research to address these limitations and improve quality of care for patients. Within the broad field of drug delivery, the development of stimuli-responsive drug delivery systems has created the ability to tune drug delivery systems to achieve more controlled dosing and targeted specificity based on material response to exogenous and endogenous stimuli.

Pullulan bioconjugates are systems that use pullulan as a scaffold to attach biological materials to, such as drugs. These systems can be used to enhance the delivery of drugs to specific environments or the mechanism of delivery. These systems can be used in order to deliver drugs in response to stimuli, create a more controlled and sustained release, and provide a more targeted delivery of certain drugs.

<span class="mw-page-title-main">Reduction-sensitive nanoparticles</span> Drug delivery method

Reduction-sensitive nanoparticles (RSNP) consist of nanocarriers that are chemically responsive to reduction. Drug delivery systems using RSNP can be loaded with different drugs that are designed to be released within a concentrated reducing environment, such as the tumor-targeted microenvironment. Reduction-Sensitive Nanoparticles provide an efficient method of targeted drug delivery for the improved controlled release of medication within localized areas of the body.

Ultrasound-triggered drug delivery using stimuli-responsive hydrogels refers to the process of using ultrasound energy for inducing drug release from hydrogels that are sensitive to acoustic stimuli. This method of approach is one of many stimuli-responsive drug delivery-based systems that has gained traction in recent years due to its demonstration of localization and specificity of disease treatment. Although recent developments in this field highlight its potential in treating certain diseases such as COVID-19, there remain many major challenges that need to be addressed and overcome before more related biomedical applications are clinically translated into standard of care.

Intranasal drug delivery occurs when particles are inhaled into the nasal cavity and transported directly into the nervous system. Though pharmaceuticals can be injected into the nose, some concerns include injuries, infection, and safe disposal. Studies demonstrate improved patient compliance with inhalation. Treating brain diseases has been a challenge due to the blood brain barrier. Previous studies evaluated the efficacy of delivery therapeutics through intranasal route for brain diseases and mental health conditions. Intranasal administration is a potential route associated with high drug transfer from nose to brain and drug bioavailability.

<span class="mw-page-title-main">Ligand-targeted liposome</span> Ligand-targeted liposomes for use in medical applications

A ligand-targeted liposome (LTL) is a nanocarrier with specific ligands attached to its surface to enhance localization for targeted drug delivery. The targeting ability of LTLs enhances cellular localization and uptake of these liposomes for therapeutic or diagnostic purposes. LTLs have the potential to enhance drug delivery by decreasing peripheral systemic toxicity, increasing in vivo drug stability, enhancing cellular uptake, and increasing efficiency for chemotherapeutics and other applications. Liposomes are beneficial in therapeutic manufacturing because of low batch-to-batch variability, easy synthesis, favorable scalability, and strong biocompatibility. Ligand-targeting technology enhances liposomes by adding targeting properties for directed drug delivery.

<span class="mw-page-title-main">Intravesical drug delivery</span> Intravesical drug delivery, drug delivery to the bladder

Intravesical drug delivery is the delivery of medications directly into the bladder by urinary catheter. This method of drug delivery is used to directly target diseases of the bladder such as interstitial cystitis and bladder cancer, but currently faces obstacles such as low drug retention time due to washing out with urine and issues with the low permeability of the bladder wall itself. Due to the advantages of directly targeting the bladder, as well as the effectiveness of permeability enhancers, advances in intravesical drug carriers, and mucoadhesive, intravesical drug delivery is becoming more effective and of increased interest in the medical community.

<span class="mw-page-title-main">Artificial white blood cells</span> Alternative method of immunotherapy

Artificial white blood cells are typically membrane bound vesicles designed to mimic the immunomodulatory behavior of naturally produced leukocytes. While extensive research has been done with regards to artificial red blood cells and platelets for use in emergency blood transfusions, research into artificial white blood cells has been focused on increasing the immunogenic response within a host to treat cancer or deliver drugs in a more favorable fashion. While certain limitations have prevented leukocyte mimicking particles from becoming widely used and FDA approved, more research is being allocated to this area of synthetic blood which has the potential for producing a new form of treatment for cancer and other diseases.

References

  1. 1 2 Muller, R; Keck, C (2004). "Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles". Journal of Biotechnology. 113 (1–3): 151–170. doi : 10.1016/j.jbiotec.2004.06.007...https://www.accessscience.com/content/article/a757275
  2. ↑ Tiwari, Gaurav; Tiwari, Ruchi; Sriwastawa, Birendra; Bhati, L; Pandey, S; Pandey, P; Bannerjee, Saurabh K (2012). "Drug delivery systems: An updated review"
  3. ↑ Abu-Thabit, Nedal Y.; Makhlouf, Abdel Salam H. (2018-01-01), Makhlouf, Abdel Salam Hamdy; Abu-Thabit, Nedal Y. (eds.), "1 - Historical development of drug delivery systems: From conventional macroscale to controlled, targeted, and responsive nanoscale systems"
  4. ↑ Zhang, Xiaomeng; Lin, Yuxiang; Gillies, Robert J. (August 2010). "Tumor pH and Its Measurement". Journal of Nuclear Medicine. 51 (8): 1167–1170. doi:10.2967/jnumed.109.068981. ISSN   0161-5505. PMC   4351768 . PMID   20660380.
  5. ↑ Pillai, Smitha R.; Damaghi, Mehdi; Marunaka, Yoshinori; Spugnini, Enrico Pierluigi; Fais, Stefano; Gillies, Robert J. (June 2019). "Causes, consequences, and therapy of tumors acidosis". Cancer and Metastasis Reviews. 38 (1–2): 205–222. doi:10.1007/s10555-019-09792-7. ISSN   0167-7659. PMC   6625890 . PMID   30911978.
  6. ↑ Gilkes, Daniele M.; Semenza, Gregg L.; Wirtz, Denis (June 2014). "Hypoxia and the extracellular matrix: drivers of tumour metastasis". Nature Reviews Cancer. 14 (6): 430–439. doi:10.1038/nrc3726. ISSN   1474-175X. PMC   4283800 . PMID   24827502.
  7. 1 2 Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033. doi : 10.1126/science.1160809
  8. 1 2 Liberti, Maria V.; Locasale, Jason W. (2016-03-01). "The Warburg Effect: How Does it Benefit Cancer Cells?". Trends in Biochemical Sciences. 41 (3): 211–218. doi:10.1016/j.tibs.2015.12.001. ISSN   0968-0004. PMC   4783224 . PMID   26778478.
  9. ↑ Kato, Yasumasa; Ozawa, Shigeyuki; Miyamoto, Chihiro; Maehata, Yojiro; Suzuki, Atsuko; Maeda, Toyonobu; Baba, Yuh (2013-09-03). "Acidic extracellular microenvironment and cancer". Cancer Cell International. 13 (1): 89. doi: 10.1186/1475-2867-13-89 . ISSN   1475-2867. PMC   3849184 . PMID   24004445.
  10. 1 2 3 4 5 6 7 AlSawaftah, Nour M.; Awad, Nahid S.; Pitt, William G.; Husseini, Ghaleb A. (2022-02-26). "pH-Responsive Nanocarriers in Cancer Therapy". Polymers. 14 (5): 936. doi: 10.3390/polym14050936 . ISSN   2073-4360. PMC   8912405 . PMID   35267759.
  11. 1 2 Chu, Shunli; Shi, Xiaolu; Tian, Ye; Gao, Fengxiang (2022-03-22). "pH-Responsive Polymer Nanomaterials for Tumor Therapy". Frontiers in Oncology. 12: 855019. doi: 10.3389/fonc.2022.855019 . ISSN   2234-943X. PMC   8980858 . PMID   35392227.
  12. 1 2 3 4 5 Zhuo, Shijie; Zhang, Feng; Yu, Junyu; Zhang, Xican; Yang, Guangbao; Liu, Xiaowen (January 2020). "pH-Sensitive Biomaterials for Drug Delivery". Molecules. 25 (23): 5649. doi: 10.3390/molecules25235649 . ISSN   1420-3049. PMC   7730929 . PMID   33266162.
  13. 1 2 Tang, Houliang; Zhao, Weilong; Yu, Jinming; Li, Yang; Zhao, Chao (2018-12-20). "Recent Development of pH-Responsive Polymers for Cancer Nanomedicine". Molecules. 24 (1): 4. doi: 10.3390/molecules24010004 . ISSN   1420-3049. PMC   6337262 . PMID   30577475.
  14. ↑ DING, Bao-yue; AO, lei; DING, Xue-ying; GAO, Jing; FAN, Wei; GAO, Shen (2010-04-13). "Active tumor targeting drug delivery system: the current status". Academic Journal of Second Military Medical University. 30 (3): 321–328. doi:10.3724/sp.j.1008.2010.00321. ISSN   0258-879X.
  15. ↑ Palanikumar, L.; Al-Hosani, Sumaya; Kalmouni, Mona; Nguyen, Vanessa P.; Ali, Liaqat; Pasricha, Renu; Barrera, Francisco N.; Magzoub, Mazin (2020-03-03). "pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics". Communications Biology. 3 (1): 95. doi:10.1038/s42003-020-0817-4. ISSN   2399-3642. PMC   7054360 . PMID   32127636.
  16. ↑ Liu J, Huang Y, Kumar A, Tan A, Jin S, Mozhi A, Liang XJ. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv. 2014 Jul-Aug;32(4):693-710. doi : 10.1016/j.biotechadv.2013.11.009 Epub 2013 Dec 3. PMID 24309541.
  17. ↑ Adepu, Shivakalyani; Ramakrishna, Seeram (January 2021). "Controlled Drug Delivery Systems: Current Status and Future Directions". Molecules. 26 (19): 5905. doi: 10.3390/molecules26195905 . ISSN   1420-3049. PMC   8512302 . PMID   34641447.
  18. ↑ Rizwan, Muhammad; Yahya, Rosiyah; Hassan, Aziz; Yar, Muhammad; Azzahari, Ahmad; Selvanathan, Vidhya; Sonsudin, Faridah; Abouloula, Cheyma (2017-04-12). "pH Sensitive Hydrogels in Drug Delivery: Brief History, Properties, Swelling, and Release Mechanism, Material Selection and Applications". Polymers. 9 (12): 137. doi: 10.3390/polym9040137 . ISSN   2073-4360. PMC   6432076 . PMID   30970818.
  19. 1 2 3 Cirillo G, Spizzirri UG, Curcio M, Nicoletta FP, Iemma F. Injectable Hydrogels for Cancer Therapy over the Last Decade. Pharmaceutics. 2019; 11(9):486. doi : 10.3390/pharmaceutics11090486
  20. ↑ Abulateefeh, S.R. Long-acting injectable PLGA/PLA depots for leuprolide acetate: successful translation from bench to clinic. Drug Deliv. and Transl. Res. (2022). doi : 10.1007/s13346-022-01228-0
  21. ↑ Torchilin, V (2006). "Multifunctional nanocarriers". Advanced Drug Delivery Reviews. 58 (14): 1532–55. doi : 10.1016/j.addr.2006.09.009 PMID 17092599. S2CID 9464592
  22. ↑ Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid Nanoparticles─From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano. 2021 Nov 23;15(11):16982-17015. doi : 10.1021/acsnano.1c04996 Epub 2021 Jun 28. PMID 34181394.
  23. 1 2 Paliwal, Shivani Rai; Paliwal, Rishi; Vyas, Suresh P. (2015-04-03). "A review of mechanistic insight and application of pH-sensitive liposomes in drug delivery". Drug Delivery. 22 (3): 231–242. doi:10.3109/10717544.2014.882469. ISSN   1071-7544.
  24. ↑ Lee, Y.; Thompson, D.H. (September 2017). "Stimuli‐responsive liposomes for drug delivery". WIREs Nanomedicine and Nanobiotechnology. 9 (5). doi:10.1002/wnan.1450. ISSN   1939-5116. PMID   28198148.
  25. ↑ Song, Jian; Xu, Bingbing; Yao, Hui; Lu, Xiaofang; Tan, Yang; Wang, Bingyang; Wang, Xing; Yang, Zheng (2021). "Schiff-Linked PEGylated Doxorubicin Prodrug Forming pH-Responsive Nanoparticles With High Drug Loading and Effective Anticancer Therapy". Frontiers in Oncology. 11: 656717. doi: 10.3389/fonc.2021.656717 . ISSN   2234-943X. PMC   8027505 . PMID   33842372.
  26. ↑ Zhang, Xiaoli; Zhang, Tian; Ma, Xianbin; Wang, Yajun; Lu, Yi; Jia, Die; Huang, Xiaohua; Chen, Jiucun; Xu, Zhigang; Wen, Feiqiu (September 2020). "The design and synthesis of dextran-doxorubicin prodrug-based pH-sensitive drug delivery system for improving chemotherapy efficacy". Asian Journal of Pharmaceutical Sciences. 15 (5): 605–616. doi:10.1016/j.ajps.2019.10.001. PMC   7610203 . PMID   33193863.
  27. 1 2 3 4 Hoffman, Allan S. (2013-01-01). "Stimuli-responsive polymers: Biomedical applications and challenges for clinical translation". Advanced Drug Delivery Reviews. Advanced Drug Delivery: Perspectives and Prospects. 65 (1): 10–16. doi:10.1016/j.addr.2012.11.004. ISSN   0169-409X. PMID   23246762.
  28. ↑ Chien, Jenny Y.; Ho, Rodney J.Y. (January 2011). "Drug Delivery Trends in Clinical Trials and Translational Medicine: Evaluation of Pharmacokinetic Properties in Special Populations". Journal of Pharmaceutical Sciences. 100 (1): 53–58. doi:10.1002/jps.22253. PMC   4867146 . PMID   20589750.
  29. ↑ Wang, Lei; Niu, Xiuxiu; Song, Qingling; Jia, Jiajia; Hao, Yongwei; Zheng, Cuixia; Ding, Kaili; Xiao, Huifang; Liu, Xinxin; Zhang, Zhenzhong; Zhang, Yun (February 2020). "A two-step precise targeting nanoplatform for tumor therapy via the alkyl radicals activated by the microenvironment of organelles". Journal of Controlled Release. 318: 197–209. doi:10.1016/j.jconrel.2019.10.017. ISSN   0168-3659. PMID   31672622. S2CID   207814978.
  30. ↑ Saw, Phei Er; Yao, Herui; Lin, Chunhao; Tao, Wei; Farokhzad, Omid C; Xu, Xiaoding (2019-08-05). "Stimuli-Responsive Polymer–Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer Therapy". Nano Letters. 19 (9): 5967–5974. doi:10.1021/acs.nanolett.9b01660. ISSN   1530-6984. PMID   31381852. S2CID   199451878.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.